These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17289176)

  • 1. Angiographic and intravascular ultrasound study of the effects of overlapping sirolimus- and paclitaxel-eluting stents: comparison with same drug-eluting overlapping stents.
    Kang WC; Oh KJ; Han SH; Ahn TH; Chung WJ; Shin MS; Koh KK; Choi IS; Shin EK
    Int J Cardiol; 2007 Dec; 123(1):12-7. PubMed ID: 17289176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of drug-eluting stent implantation for patients with unprotected left main coronary artery stenosis.
    Kim YH; Dangas GD; Solinas E; Aoki J; Parise H; Kimura M; Franklin-Bond T; Dasgupta NK; Kirtane AJ; Moussa I; Lansky AJ; Collins M; Stone GW; Leon MB; Moses JW; Mehran R
    Am J Cardiol; 2008 Mar; 101(6):801-6. PubMed ID: 18328844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evaluation of paclitaxel-coated stents for treatment of native coronary lesions. First results of both the clinical and angiographic 18 month follow-up of TAXUS I.
    Büllesfeld L; Gerckens U; Müller R; Grube E
    Z Kardiol; 2003 Oct; 92(10):825-32. PubMed ID: 14579046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up.
    Rensing BJ; Vos J; Smits PC; Foley DP; van den Brand MJ; van der Giessen WJ; de Feijter PJ; Serruys PW
    Eur Heart J; 2001 Nov; 22(22):2125-30. PubMed ID: 11686669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of overlapping heterogenous drug-eluting stents and of overlapping drug-eluting and bare metal stents.
    Burzotta F; Siviglia M; Altamura L; Trani C; Leone AM; Romagnoli E; Mazzari MA; Mongiardo R; Niccoli G; Brancati M; Biondi-Zoccai G; Rebuzzi AG; Schiavoni G; Crea F
    Am J Cardiol; 2007 Feb; 99(3):364-8. PubMed ID: 17261399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of stem cell therapy with G-CSF on coronary artery after drug-eluting stent implantation in patients with acute myocardial infarction.
    Kang HJ; Kim YS; Koo BK; Park KW; Lee HY; Sohn DW; Oh BH; Park YB; Kim HS
    Heart; 2008 May; 94(5):604-9. PubMed ID: 18070947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of drug-eluting versus bare metal stents on later frequency of acute myocardial infarction and death.
    Applegate RJ; Sacrinty MT; Kutcher MA; Baki TT; Gandhi SK; Santos RM; Little WC
    Am J Cardiol; 2007 Feb; 99(3):333-8. PubMed ID: 17261393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: late "catch-up" phenomenon from ASPECT Study.
    Park DW; Hong MK; Mintz GS; Lee CW; Song JM; Han KH; Kang DH; Cheong SS; Song JK; Kim JJ; Weissman NJ; Park SW; Park SJ
    J Am Coll Cardiol; 2006 Dec; 48(12):2432-9. PubMed ID: 17174179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute coronary syndrome is an independent risk factor for late incomplete stent apposition after sirolimus-eluting stent implantation.
    Zhang RY; DU R; Zhu ZB; Zhang Q; Hu J; Lü AK; Zhang JS; Shen WF
    Chin Med J (Engl); 2008 Dec; 121(24):2504-8. PubMed ID: 19187586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial).
    Hirohata A; Morino Y; Ako J; Sakurai R; Buchbinder M; Caputo RP; Karas SP; Mishkel GJ; Mooney MR; O'shaughnessy CD; Raizner AE; Wilensky RL; Williams DO; Wong SC; Yock PG; Honda Y; Moses JW; Fitzgerald PJ;
    Am J Cardiol; 2006 Dec; 98(11):1464-7. PubMed ID: 17126651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-eluting stent for the treatment of small coronary lesion: comparison between sirolimus- and paclitaxel-eluting stent.
    Li JJ; Xu B; Yang YJ; Chen JL; Qiao SB; Ma WH; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J; You SJ; Dai J; Xia R; Gao RL
    Chin Med J (Engl); 2007 Apr; 120(7):569-73. PubMed ID: 17442204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six-month comparison of coronary endothelial dysfunction associated with sirolimus-eluting stent versus Paclitaxel-eluting stent.
    Kim JW; Suh SY; Choi CU; Na JO; Kim EJ; Rha SW; Park CG; Seo HS; Oh DJ
    JACC Cardiovasc Interv; 2008 Feb; 1(1):65-71. PubMed ID: 19393147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up.
    Park DW; Park SW; Park KH; Lee BK; Kim YH; Lee CW; Hong MK; Kim JJ; Park SJ
    Am J Cardiol; 2006 Aug; 98(3):352-6. PubMed ID: 16860022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.
    Finn AV; Kolodgie FD; Harnek J; Guerrero LJ; Acampado E; Tefera K; Skorija K; Weber DK; Gold HK; Virmani R
    Circulation; 2005 Jul; 112(2):270-8. PubMed ID: 15998681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss.
    Mehilli J; Kastrati A; Wessely R; Dibra A; Hausleiter J; Jaschke B; Dirschinger J; Schömig A;
    Circulation; 2006 Jan; 113(2):273-9. PubMed ID: 16391155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of bare-metal and sirolimus- or paclitaxel-eluting stents for aorto-ostial coronary disease.
    Barlis P; Kaplan S; Dimopoulos K; Ferrante G; Di Mario C
    Cardiology; 2008; 111(4):270-6. PubMed ID: 18451644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
    Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
    Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
    Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
    Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions.
    Iofina E; Langenberg R; Blindt R; Kühl H; Kelm M; Hoffmann R
    Am J Cardiol; 2006 Oct; 98(8):1022-7. PubMed ID: 17027564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.